{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:25:07Z","timestamp":1792171507144,"version":"4.4.0"},"reference-count":8,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v105.43999","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:41:37Z","timestamp":1751370097000},"page":"adv43999","source":"Crossref","is-referenced-by-count":2,"title":["Dupilumab Achieves Early Disease Control in Bullous Pemphigoid: A Case Series with TARC-based Biomarker Evaluation"],"prefix":"10.2340","volume":"105","author":[{"given":"Saori","family":"Takamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"116802","doi-asserted-by":"crossref","unstructured":"Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res 2018; 66: 6\u201317.","DOI":"10.1007\/s12026-017-8975-2"},{"key":"116803","doi-asserted-by":"crossref","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335\u20132348.","DOI":"10.1056\/NEJMoa1610020"},{"key":"116804","doi-asserted-by":"crossref","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 2022; 13: 928621.","DOI":"10.3389\/fimmu.2022.928621"},{"key":"116805","doi-asserted-by":"crossref","unstructured":"Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol 2023; 159: 953\u2013960.","DOI":"10.1001\/jamadermatol.2023.2428"},{"key":"116806","doi-asserted-by":"crossref","unstructured":"Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study. Int Immunopharmacol 2023; 125: 111157.","DOI":"10.1016\/j.intimp.2023.111157"},{"key":"116807","doi-asserted-by":"crossref","unstructured":"Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107: 535\u2013541.","DOI":"10.1067\/mai.2001.113237"},{"key":"116808","doi-asserted-by":"crossref","unstructured":"Kakinuma T, Wakugawa M, Nakamura K, Hino H, Matsushima K, Tamaki K. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br J Dermatol 2003; 148: 203\u2013210.","DOI":"10.1046\/j.1365-2133.2003.05066.x"},{"key":"116809","doi-asserted-by":"crossref","unstructured":"Suzuki M, Yamaguchi Y, Nakamura K, Kanaoka M, Matsukura S, Takahashi K, et al. Serum thymus and activation-regulated chemokine (TARC\/CCL17) may be useful to predict the disease activity in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2021; 35: e121\u2013e124.","DOI":"10.1111\/jdv.16851"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43999\/50636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43999\/50636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:41:40Z","timestamp":1751370100000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":8,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43999","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}